Navigation Links
Deadly E. Coli Strain Sequenced With Roche GS Junior System by HPA Scientists - Provides Community Most Complete Assembly to Date

BRANFORD, Connecticut, June 15, 2011 /PRNewswire/ --

The deadly E. coli O104 strain that has killed dozens and hospitalized thousands across Europe has been sequenced using 454 Life Sciences' benchtop GS Junior sequencing system to generate the "most accurate and detailed genetic analysis to date" of this particularly virulent strain.[1] The sequencing was performed by scientists at the UK's Health Protection Agency and the data has been uploaded onto the National Centre for Biotechnology Information (NCBI) website for use by the scientific community.[2]

The results suggest that the strain has a unique combination of features containing genes from two different types of E. coli as well as its own genes. The sequencing assembly shows that the strain contains two extrachromosomal elements or plasmids which may factor into its pathogenicity. In essence, this strain of E. coli may have 'picked up' some extra genetic material along the way.

"Despite the availability of short read sequencing data from this E. coli outbreak strain for over a week, the short fragmented assembly has offered only limited information on gene order and gene composition," said Chinnappa Kodira, Director of Genomics at 454 Life Sciences. "This long contiguous assembly enables much better characterization of genome structure, horizontal gene transfer and pathogenic islands which are crucial for understanding the emergence of new virulent bacterial strains." The addition of this new long read sequence data from the GS Junior System offers the community the most contiguous sequence to date, and provides a comprehensive assembly on which subsequent genomic analysis can be performed.

The long shotgun reads generated using the 454 Sequencing System allowed the HPA scientists to assemble almost the entire genome into a comprehensive and detailed genomic map of this pathogen within hours. The sequence data will assist in on-going efforts to identify the source of the outbreak, and understand how the strain may have evolved.

"The combination of fast turnaround time and high-quality, long sequencing reads makes the GS Junior an ideal research platform for rapid and comprehensive whole genome analysis in novel pathogen outbreak situations," said Christopher McLeod, President and CEO of 454 Life Sciences. "We are gratified that 454 Life Sciences is helping to improve health care by enabling a quick response to shed some light on potential epidemics."

For more information on 454 Sequencing Systems, visit

[1]Health Protection Agency press release June 13, 2011:

[2]The sequence data can be viewed on the NCBI website The GeneBank Project ID is 67929 and the accession number is afpn00000000. The data can also be viewed on the HPA website:

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80'000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information:

For life science research only. Not for use in diagnostic procedures.

454, 454 LIFE SCIENCES, 454 SEQUENCING, and GS JUNIOR are trademarks of Roche.

Other brands or product names are trademarks of their respective holders.

For further information please contact: 454 Life Sciences Corporation, a Roche Diagnostics Roche Company Dr. Burkhard Ziebolz Dr. Ulrich Schwoerer Phone: +49-8856-604830 Phone: +1-203-871-2300 Email: Email:

SOURCE Roche Diagnostics GmbH
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. American Heart Association EMS Survey Uncovers Deficiencies in Response, Treatment and Transfer of Patients With Most Deadly Heart Attacks
2. Consumers at Risk: One in Six Wood Pallets in Los Angeles Discovered With Potentially Deadly Pathogens
3. New Study Released Today Showed Patients With Deadly Form of Lung Cancer Lived Longer Without Disease Worsening
4. Life Technologies Develops Fast and Accurate Test to Detect Europes Deadly E. coli
5. Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
6. Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions
7. New Study Shows Probiotic Strain Effective in Improving Irritable Bowel Syndrome Symptoms
8. New Study Shows Probiotic Strain Effective in Boosting Immune Response to Flu Virus
9. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
10. Lakewood-Amedex Inc. to Develop Broad Spectrum Influenza Drug to Include H1N1 and H5N1 Type A Strains
11. Adamas Pharmaceuticals Announces In Vitro Data Demonstrating TCAD Therapy is More Potent Than Double Combinations or Monotherapy Against Drug-Resistant Flu Strains
Post Your Comments:
(Date:11/24/2015)... DELHI , November 25, 2015 ... invoked due to repeated failure of IVF cycles. After ... Bhatia was totally dejected and had lost all hopes that she would be ... first Indian miracle child conceived after failure of over ... to abroad (UK) before they decided to take one last attempt ...
(Date:11/24/2015)...  In the pharmaceutical industry, companies want to rapidly ... uncover new insights, tactics and strategies that will improve ... --> However, organizations often find it is difficult ... that all rules and regulations are met to ensure ... to efficiently launching market research projects is the conflicting ...
(Date:11/24/2015)... , November 24, 2015 --> ... report "Spine Biologics Market by Product Type (Bone Graft, Bine ... Discectomy and Fusion, Posterior Lumbar Interbody Fusion), End User, and ... global market was valued at $1.90 Billion in 2014 and ... CAGR of 4.4% during the forecast period of 2015 to ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... ... Serenity Point Rehabilitation, a holistic treatment center for substance abuse located in ... staff members at their recovery center. The videos highlight some of the various aspects ... things that make their recovery program so unique. , “Making the decision to seek ...
(Date:11/24/2015)... ... November 24, 2015 , ... Cold Shoulder , LLC launched their Pro Vest, the latest ... hit their goal of $20,000 in under 10 hours. , The campaign, ... PRO Weight Loss Vest to the market. , The PRO Vest provides consumers with a ...
(Date:11/24/2015)... ... ... Dr. Rodney E. Willey , has answered a new calling – to relieve snoring ... treatment for snoring and sleep apnea through oral appliance therapy. He is ... in the US, one of four in the Illinois area. , Dr. Willey’s ...
(Date:11/24/2015)... ... ... Bibliomotion is thrilled to announce the launch of UNCONVENTIONAL ... Nancy M. Schlichting, Chief Executive Officer of Henry Ford Health System (November ... of patients and their families, shaped my desire to improve the system of care. ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... products, announces Innovative Blending, a household invention that revolutionizes the vending machine industry ... Smoothie Bars market is worth $2 billion," says Scott Cooper, CEO and Creative ...
Breaking Medicine News(10 mins):